Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471602 | 0.83 | KMT2A (0.65) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL5283007 | 0.77 | SCD (0.45) | KMT2AMEN1 | |
| SCHEMBL5289213 | 0.77 | SCD (0.48) | KMT2AMEN1MAPT | |
| SCHEMBL1471495 | 0.73 | TP53 (0.62) | KMT2ALMNACYP2C19CYP1A2MEN1 | |
| SCHEMBL3222938 | 0.73 | MEN1 (0.63) | KMT2AALDH1A1LMNACYP2C19CYP2C9 | |
| SCHEMBL6685830 | 0.72 | UTS2R (0.63) | KMT2AALDH1A1LMNAMEN1MAPT | |
| SCHEMBL1471706 | 0.72 | HSD11B1 (0.54) | KMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL3223105 | 0.71 | KMT2A (0.60) | KMT2AALDH1A1LMNAMEN1GAA | |
| SCHEMBL5244612 | 0.71 | NPC1 (0.53) | KMT2AMAPT | |
| SCHEMBL6985771 | 0.71 | KMT2A (0.79) | KMT2AALDH1A1LMNACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | KMT2A 1303/4885ALDH1A1 2627/4885LMNA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.